Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Haibang Capital

Investor type Venture Capital
Founders Gang Liang Li Xie Naxin Yao


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 28
Average round size
The average size of a deal this fund participated in
Portfolio companies 25
Rounds per year 2.55
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 2
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Medical Device
  • Health Care
  • Medical
  • Biotechnology
  • Manufacturing

In 2011 was created Haibang Capital, which is appeared as VC. The main department of described VC is located in the Hangzhou. The company was established in Asia in China.

Among the most successful fund investment fields, there are Medical, Psychology. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Zylox, Zylox, IMPACT Therapeutics For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Haibang Capital, startups are often financed by Yueyin Venture Capital, WuXi Healthcare Ventures, Proxima Ventures Ltd. The meaningful sponsors for the fund in investment in the same round are Juren Capital, Highlight Capital, Yueyin Venture Capital. In the next rounds fund is usually obtained by SDIC Fund Management, Lilly Asia Ventures, Juren Capital.

The usual things for fund are deals in the range of 5 - 10 millions dollars. The important activity for fund was in 2015. The fund is constantly included in less than 2 investment rounds annually. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations.

The current fund was established by Gang Liang, Li Xie, Naxin Yao.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Haibang Capital:
Typical Co-investors
Haibang Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Haibang Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Connor Capital SB -
iQiyi Sports Beijing, Beijing, China
IT Co -
Jipyong Seoul, Seoul-t'ukpyolsi, South Korea
Madison Capital Partners Chicago, Illinois, United States
Novartis Basel, Basel-Stadt, Switzerland
Oikocredit International Amersfoort, The Netherlands, Utrecht
Pine Street Capital Partners Massachusetts, United States, Wellesley
TOS TV OITA Japan, Tokyo
Zhangke Lingyi Investment China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Hengyu Biotechnology

Health Care
Information Technology
25 Jul 2022 Jiaxing, Zhejiang, China


Medical Device
$77M21 Feb 2022 Jiaxing, Zhejiang, China

Jiu Zong

Machinery Manufacturing
Test and Measurement
12 Nov 2021 Ningbo, Zhejiang, China


E-Commerce Platforms
$15M01 Nov 2021 Shanghai, Shanghai, China


Health Care
Product Research
20 Aug 2021 Suzhou, Jiangsu, China

Realmind Biotech

Health Diagnostics
Medical Device
19 Jul 2021 Nanjing, Jiangsu, China

TYK Medicines

Health Care
Product Research
$61M23 May 2021 Shanghai, Shanghai, China

Medical Device
22 Feb 2021 Shangcheng District, Zhejiang, China

Sciwind Biosciences

Health Care
$37M18 Feb 2021 China, Zhejiang
Sciwind Biosciences Secures US$37 Million Series B Financing

– Sciwind biosciences secured US$37m series B financing.
– The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.
– Sciwind focuses on research and development of innovative biologics in the therapeutic area of chronic metabolic and immunological diseases and has driven multiple projects into clinical trials.
– Two more IND applications are expected to be filed in 2021 including an oral formulation of a highly active GLP-1 analogue.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Haibang Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: